OBJECTIVE: We examined the association between NSAID use and breast cancer recurrence in a prospective cohort of 2,292 early-stage breast cancer survivors diagnosed from 1997 to 2000 participating in the Life After Cancer Epidemiology (LACE) Study. METHODS: From 2000 to 2002, mailed questionnaires were used to obtain information on aspirin, ibuprofen, and other NSAID use and subsequent breast cancer events. A total of 270 recurrences (local, regional, and distant disease and new primary breast cancers) were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI), adjusting for age at diagnosis, race, cancer stage, tamoxifen treatment, chemotherapy use, body mass index, and cyclooxygenase-2 (COX2) inhibitor use. RESULTS: Current, regular use (at least three days per week at time of questionnaire administration) of ibuprofen (RR, 0.56; 95% CI, 0.32-0.98), but not aspirin (RR, 1.09; 95% CI, 0.74-1.61), was associated with a statistically significant decreased risk of breast cancer recurrence. The combination of ibuprofen and other non-aspirin NSAIDs such as naproxen and sulindac reflected a similar reduction in risk (RR, 0.56; 95% CI, 0.33-0.95). No association was found for the non-NSAID analgesic acetaminophen. CONCLUSION: Our findings provide support for an inverse association between current, regular ibuprofen use and breast cancer recurrence.
OBJECTIVE: We examined the association between NSAID use and breast cancer recurrence in a prospective cohort of 2,292 early-stage breast cancer survivors diagnosed from 1997 to 2000 participating in the Life After Cancer Epidemiology (LACE) Study. METHODS: From 2000 to 2002, mailed questionnaires were used to obtain information on aspirin, ibuprofen, and other NSAID use and subsequent breast cancer events. A total of 270 recurrences (local, regional, and distant disease and new primary breast cancers) were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI), adjusting for age at diagnosis, race, cancer stage, tamoxifen treatment, chemotherapy use, body mass index, and cyclooxygenase-2 (COX2) inhibitor use. RESULTS: Current, regular use (at least three days per week at time of questionnaire administration) of ibuprofen (RR, 0.56; 95% CI, 0.32-0.98), but not aspirin (RR, 1.09; 95% CI, 0.74-1.61), was associated with a statistically significant decreased risk of breast cancer recurrence. The combination of ibuprofen and other non-aspirin NSAIDs such as naproxen and sulindac reflected a similar reduction in risk (RR, 0.56; 95% CI, 0.33-0.95). No association was found for the non-NSAID analgesic acetaminophen. CONCLUSION: Our findings provide support for an inverse association between current, regular ibuprofen use and breast cancer recurrence.
Authors: F M Robertson; M L Parrett; F S Joarder; M Ross; H M Abou-Issa; G Alshafie; R E Harris Journal: Cancer Lett Date: 1998-01-09 Impact factor: 8.679
Authors: Sarah F Marshall; Leslie Bernstein; Hoda Anton-Culver; Dennis Deapen; Pamela L Horn-Ross; Harvey Mohrenweiser; David Peel; Rich Pinder; David M Purdie; Peggy Reynolds; Dan Stram; Dee West; William E Wright; Argyrios Ziogas; Ronald K Ross Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Eric J Jacobs; Michael J Thun; Cari J Connell; Carmen Rodriguez; S Jane Henley; Heather S Feigelson; Alpa V Patel; W Dana Flanders; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-01 Impact factor: 4.254
Authors: Bette Caan; Barbara Sternfeld; Erica Gunderson; Ashley Coates; Charles Quesenberry; Martha L Slattery Journal: Cancer Causes Control Date: 2005-06 Impact factor: 2.506
Authors: Jessica Chubak; Denise M Boudreau; Heidi S Wirtz; Barbara McKnight; Noel S Weiss Journal: J Natl Cancer Inst Date: 2013-08-12 Impact factor: 13.506
Authors: Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash Journal: J Natl Cancer Inst Date: 2011-08-02 Impact factor: 13.506
Authors: Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2011-07-05 Impact factor: 4.872
Authors: Karla Esbona; Yanyao Yi; Sandeep Saha; Menggang Yu; Rachel R Van Doorn; Matthew W Conklin; Douglas S Graham; Kari B Wisinski; Suzanne M Ponik; Kevin W Eliceiri; Lee G Wilke; Patricia J Keely Journal: Am J Pathol Date: 2018-03 Impact factor: 4.307
Authors: Brian L Sprague; Amy Trentham-Dietz; Hazel B Nichols; John M Hampton; Polly A Newcomb Journal: Breast Cancer Res Treat Date: 2010-04-02 Impact factor: 4.872
Authors: Mehmet A N Sendur; Sercan Aksoy; Nuriye Y Ozdemir; Nurullah Zengin; Kadri Altundag Journal: Breast Care (Basel) Date: 2014-04 Impact factor: 2.860